Processa Pharmaceuticals (NASDAQ: PCSA) announced its participation in the 2025 BIO International Convention in Boston from June 16-19, 2025. CEO Georg Ng and President R&D Dr. David Young will conduct one-on-one meetings with potential partners and investors to discuss the company's strategic direction and clinical developments. The meetings will focus on their Next Generation Cancer (NGC) platform, particularly their lead asset NGC-Cap, which is in Phase 2 trials for metastatic breast cancer. The BIO International Convention is the biotechnology industry's largest gathering, attracting over 20,000 global leaders for networking and collaboration opportunities.
Processa Pharmaceuticals (NASDAQ: PCSA) ha annunciato la sua partecipazione alla BIO International Convention 2025 che si terrà a Boston dal 16 al 19 giugno 2025. Il CEO Georg Ng e il Presidente R&D, Dr. David Young, terranno incontri individuali con potenziali partner e investitori per discutere la direzione strategica dell'azienda e gli sviluppi clinici. Le riunioni si concentreranno sulla loro piattaforma Next Generation Cancer (NGC), in particolare sul loro principale prodotto NGC-Cap, attualmente in fase 2 di sperimentazione per il trattamento del cancro al seno metastatico. La BIO International Convention è il più grande evento del settore biotecnologico, che attira oltre 20.000 leader mondiali per opportunità di networking e collaborazione.
Processa Pharmaceuticals (NASDAQ: PCSA) anunció su participación en la Convención Internacional BIO 2025 que se celebrará en Boston del 16 al 19 de junio de 2025. El CEO Georg Ng y el presidente de I+D, Dr. David Young, mantendrán reuniones individuales con posibles socios e inversores para discutir la dirección estratégica de la empresa y los avances clínicos. Las reuniones se centrarán en su plataforma Next Generation Cancer (NGC), especialmente en su principal activo NGC-Cap, que se encuentra en ensayos de fase 2 para el cáncer de mama metastásico. La Convención Internacional BIO es la mayor reunión de la industria biotecnológica, que atrae a más de 20,000 líderes globales para oportunidades de networking y colaboración.
Processa Pharmaceuticals(NASDAQ: PCSA)는 2025년 6월 16일부터 19일까지 보스턴에서 열리는 2025 BIO 국제 컨벤션에 참가한다고 발표했습니다. CEO Georg Ng와 연구개발 총괄 책임자 Dr. David Young은 잠재적 파트너 및 투자자들과 일대일 미팅을 진행하여 회사의 전략 방향과 임상 개발 현황을 논의할 예정입니다. 미팅은 차세대 암 치료 플랫폼인 Next Generation Cancer(NGC), 특히 전이성 유방암을 대상으로 한 2상 시험 중인 주요 자산 NGC-Cap에 중점을 둘 것입니다. BIO 국제 컨벤션은 생명공학 산업 최대 규모의 행사로, 전 세계 20,000명 이상의 리더들이 네트워킹 및 협력 기회를 위해 모입니다.
Processa Pharmaceuticals (NASDAQ : PCSA) a annoncé sa participation à la Convention Internationale BIO 2025 qui se tiendra à Boston du 16 au 19 juin 2025. Le PDG Georg Ng et le Président R&D, Dr David Young, mèneront des réunions individuelles avec des partenaires potentiels et des investisseurs afin de discuter de la stratégie de l'entreprise et des développements cliniques. Ces rencontres se concentreront sur leur plateforme Next Generation Cancer (NGC), notamment leur principal actif NGC-Cap, actuellement en phase 2 d'essais cliniques pour le cancer du sein métastatique. La Convention Internationale BIO est le plus grand rassemblement de l'industrie biotechnologique, attirant plus de 20 000 leaders mondiaux pour des opportunités de réseautage et de collaboration.
Processa Pharmaceuticals (NASDAQ: PCSA) gab seine Teilnahme an der BIO International Convention 2025 bekannt, die vom 16. bis 19. Juni 2025 in Boston stattfindet. CEO Georg Ng und Präsident der Forschung & Entwicklung Dr. David Young werden Einzelgespräche mit potenziellen Partnern und Investoren führen, um die strategische Ausrichtung des Unternehmens und klinische Entwicklungen zu besprechen. Die Treffen konzentrieren sich auf ihre Next Generation Cancer (NGC)-Plattform, insbesondere auf ihr führendes Produkt NGC-Cap, das sich in Phase-2-Studien für metastasierten Brustkrebs befindet. Die BIO International Convention ist die größte Zusammenkunft der Biotechnologiebranche und zieht über 20.000 globale Führungskräfte für Networking- und Kooperationsmöglichkeiten an.
Positive
None.
Negative
None.
HANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that members of its executive leadership team will attend and participate in the 2025 BIO International Convention, taking place June 16-19, 2025, in Boston, Massachusetts.
During the conference, Processa’s CEO, Georg Ng and Dr. David Young, President R&D will conduct one-on-one meetings with potential partners, investors, and other industry stakeholders to provide updates on the company’s strategic direction and clinical progress. Discussions will highlight the advancement of Processa’s NGC platform, including its lead asset NGC-Cap, currently in a Phase 2 trial for metastatic breast cancer.
“The BIO International Convention presents an ideal opportunity for us to showcase the clinical potential of our NGC therapies and the strength of our Regulatory Science Approach,” said George Ng, CEO of Processa. “We look forward to engaging with prospective partners who share our commitment to developing safer, more effective cancer treatments.”
Those interested in scheduling a meeting with Processa’s management team at BIO 2025 can request a meeting through the BIO One-on-One Partnering™ system or by contacting Investor Relations at PCSA@redchip.com.
The BIO International Convention is the world’s largest gathering of the biotechnology industry, attracting more than 20,000 leaders from around the globe to foster networking, deal-making, and scientific collaboration.
About Processa Pharmaceuticals, Inc.
Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
